Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Solid Tumors 4Neoplasms 4Lymphoma 3Lymphoma, Non-Hodgkin 2Leukemia, B-Cell 2Solid Tumor 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoid Malignancy 1Leukemia, Myeloid, Acute 1Leukemia 1Hepatitis C 1Hepatitis B 1Hematologic Neoplasms 1Fibrosis 1Carcinoma, Hepatocellular 1Advanced Lung Non-Squamous Non-Small Cell Carcinoma 1

Interventions

Tenofovir 2Sorafenib 2Low-Level Light Therapy 2High-Energy Shock Waves 2sonidegib 1ruxolitinib 1navitoclax 1hepatitis B hyperimmune globulin 1bavituximab 1adefovir dipivoxil 1Viusid 1Vitamin E 1Restraint, Physical 1Physical Therapy Modalities 1Pentoxifylline 1Magnetic Resonance Spectroscopy 1Liver Transplantation 1Lamivudine 1Independent Medical Evaluation 1Gemcitabine 1Everolimus 1Erlotinib Hydrochloride 1Enkephalin, Methionine 1Dietary Supplements 1Clinical Trials as Topic 1Breath Tests 1Blood Specimen Collection 1Angptl4 protein, mouse 1Albumin-Bound Paclitaxel 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fibrosis × navitoclax × Clear all
NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡